CD8A and neoplasm: Preclinical trials showed that Ibrutinib promoted more differentiation towards anti-tumor cytotoxic CD8 T cells [151]; however, the results from the RESOLVE trial, which was designed to investigate the role of Ibrutinib in combination with G-nab-P, were disappointing [152].